Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat solid cancer tumors.
Type of Molecule
Biologic
Target
cMet
Region
n/a
| Potential Indication | Product Type | Phase (1, 2, 3, Submitted, Approved) |
|---|---|---|
| Solid Tumors | New Indication | Phase 1 |